Imilecleucel-T

Drug Profile

Imilecleucel-T

Alternative Names: Autologous T cell vaccine - Opexa Therapeutics; Tcelna; Tovaxin®

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Opexa Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies; Vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Multiple sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 06 Oct 2015 Four additional key patents issued to Opexa Therapeutics in Europe (Patent nos. 1 546 719,, 2 420 833 and 2 363 710)
  • 09 Jun 2015 Phase II development is ongoing in USA and Canada
  • 13 May 2014 Opexa Therapeutics completes enrolment in the phase IIb Abili-T trial for secondary progressive Multiple sclerosis in USA & Canada (NCT01684761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top